Skye Bioscience Inc.
SKYESkye Bioscience Inc. in brief
Skye Bioscience Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $7 M on 29 October 2026, which makes it the 26,541st largest listed company in the world and the 4,356th largest in the USA on this site. It employs about 12 people and Punit Dhillon is its chief executive. Its shares trade under the symbol SKYE (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Skye Bioscience Inc.
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1—a key GPCR involved in metabolic regulation.
We believe there is a growing demand for therapies that offer improved safety, efficacy, tolerability, quality of life and long-term health outcomes while addressing the limitations of currently approved treatments. Our objective is to drive innovation in the treatment landscape for obesity, overweight and metabolic disorders by developing potential first-in-class therapies that meet significant unmet medical needs globally.
From the company's annual report filed with the US SEC: read the report
Skye Bioscience Inc. timeline
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- ✎Renamed Load Guard Logistics, Inc.Formerly Load Guard Transportation, Inc..
- 2014
- ✎Renamed Nemus Bioscience, Inc.Formerly Load Guard Logistics, Inc..
- 2019
- ✎Renamed Emerald Bioscience, Inc.Formerly Nemus Bioscience, Inc..
- 2021
- ✎Renamed Skye Bioscience, Inc.Formerly Emerald Bioscience, Inc..
Events of Skye Bioscience Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,258 (Jan 2022) · #2,296 (Mar 2026) · #3,963 (Aug 2026) · #4,299 (Oct 2026) · #4,359 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.3×
- Free cash flow yield
- -640.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -279.3%
- Liabilities / assets
- 29.3%
- Profit per employee
- $-4.7 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-58M | $-56M | — |
| Dec 2024 | — | — | $-30M | $-27M | — |
| Dec 2023 | — | — | $-35M | $-38M | — |
| Dec 2022 | — | — | $-18M | $-19M | — |
| Dec 2021 | — | — | $-8M | $-9M | — |
| Dec 2020 | — | — | $-6M | $-7M | — |
| Dec 2019 | — | — | $-7M | $1M | — |
| Dec 2018 | — | — | $-5M | $-19M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-43M | $0M | $-43M | $-1.41 | — |
| Dec 2024 | $-25M | $2M | $-27M | $-0.73 | — |
| Dec 2023 | $-14M | $0M | $-14M | $-5.37 | — |
| Dec 2022 | $-13M | $0M | $-13M | $-8.77 | — |
| Dec 2021 | $-6M | $0M | $-7M | $-0.02 | — |
| Dec 2020 | $-6M | $0M | $-6M | $-0.03 | — |
| Dec 2019 | $-6M | — | — | $-0.05 | — |
| Dec 2018 | $-4M | $0M | $-4M | $-0.16 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportOther events
- Sep 11, 20268-KCurrent reportAgreement ended · Directors or officers changed · Other events
- Aug 24, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Aug 20, 20268-K/ACurrent report (amended)
- Aug 19, 20268-KCurrent reportListing notice
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Change in control · Directors or officers changed · Bylaws amended · Regulation FD disclosure
- Jun 23, 20268-KCurrent reportOther events
- May 29, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 15, 20268-KCurrent reportListing notice
- May 11, 202610-QQuarterly report · period to Mar 2026
- Apr 16, 2026DEF 14AProxy statement
Official filings of Skye Bioscience Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-58 M
- Net income
- $-56 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $28 M
- Total liabilities
- $8 M
- Total equity
- $20 M
As of December-2025
Top 29 institutional investors in Skye Bioscience Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | 5AM Venture Management, LLC | 981,269 | New | 2.77% | $2 M | Nov 16, 2026 |
| 2 | Versant Venture Management, LLC | 250,962 | New | 0.71% | $0 M | Nov 13, 2026 |
| 3 | Tang Capital Management LLC | 200,000 | New | 0.56% | $0 M | Nov 16, 2026 |
| 4 | Baker Bros. Advisors LP | 196,905 | New | 0.56% | $0 M | Nov 16, 2026 |
| 5 | Citadel Advisors LLC | 114,938 | New | 0.32% | $0 M | Nov 16, 2026 |
| 6 | UBS Group AG | 40,461 | New | 0.11% | $0 M | Nov 10, 2026 |
| 7 | BlackRock, Inc. | 29,107 | New | 0.08% | $0 M | Nov 13, 2026 |
| 8 | Geode Capital Management, LLC | 27,254 | New | 0.08% | $0 M | Nov 6, 2026 |
| 9 | Vanguard Capital Management LLC | 25,985 | New | 0.07% | $0 M | Nov 13, 2026 |
| 10 | Jane Street Group, LLC | 18,688 | New | 0.05% | $0 M | Nov 12, 2026 |
| 11 | Millennium Management LLC | 14,611 | New | 0.04% | $0 M | Nov 16, 2026 |
| 12 | Vanguard Fiduciary Trust Co | 11,493 | New | 0.03% | $0 M | Nov 13, 2026 |
| 13 | Virtu Financial LLC | 11,173 | New | 0.03% | $0 M | Nov 17, 2026 |
| 14 | Royal Bank Of Canada | 1,129 | New | 0.00% | $0 M | Nov 16, 2026 |
| 15 | Tower Research Capital LLC (TRC) | 1,093 | New | 0.00% | $0 M | Nov 16, 2026 |
| 16 | Vanguard Global Advisers, LLC | 569 | New | 0.00% | $0 M | Nov 13, 2026 |
| 17 | Nuveen, LLC | 295 | New | 0.00% | $0 M | Nov 10, 2026 |
| 18 | Morgan Stanley | 243 | New | 0.00% | $0 M | Nov 13, 2026 |
| 19 | Group One Trading LLC | 72 | New | 0.00% | $0 M | Nov 10, 2026 |
| 20 | National Bank Of Canada /fi/ | 50 | New | 0.00% | $0 M | Nov 16, 2026 |
| 21 | TD Waterhouse Canada Inc. | 43 | New | 0.00% | $0 M | Oct 16, 2026 |
| 22 | Robinhood Markets, Inc. | 24 | — | 0.00% | $0 M | Nov 18, 2026 |
| 23 | Luminist Capital LLC | 12 | New | 0.00% | $0 M | Nov 10, 2026 |
| 24 | Jpmorgan Chase & Co | 7 | New | 0.00% | $0 M | Nov 12, 2026 |
| 25 | Federation des caisses Desjardins du Quebec | 5 | New | 0.00% | $0 M | Nov 16, 2026 |
Show all 29: investors 26 to 29
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Rockefeller Capital Management L.P. | 4 | New | 0.00% | $0 M | Nov 13, 2026 |
| 27 | SouthState Bank Corp | 3 | New | 0.00% | $0 M | Nov 9, 2026 |
| 28 | Danske Bank A/s | 1 | New | 0.00% | $0 M | Nov 9, 2026 |
| 29 | CoreCap Advisors, LLC | 1 | New | 0.00% | $0 M | Oct 8, 2026 |
Mutual funds holding Skye Bioscience Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 561,832 | $0 M | 1.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 184,978 | $0 M | 0.52% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 132,808 | $0 M | 0.37% | <0.01% | +32% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 30,637 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 24,379 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 18,888 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 17,072 | $0 M | 0.05% | <0.01% | −3.3% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Skye Bioscience Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Andrew J. SchwabDirector, 10% owner | Sellindirect | -114,851 | $1.610 | — | 0 | Form 4 |
| filed | 5AM Ventures II LP10% owner | Sellindirect | -114,851 | $1.610 | $185 K | 0 | Form 4 |
| filed | Andrew J. SchwabDirector, 10% owner | Sellindirect | -4,528 | $1.610 | — | 0 | Form 4 |
| filed | 5AM Ventures II LP10% owner | Sellindirect | -4,528 | $1.610 | $7 K | 0 | Form 4 |
| filed | 5AM Ventures II LP10% owner | Sellindirect | -27,612 | $1.650 | $46 K | 114,851 | Form 4 |
| filed | Andrew J. SchwabDirector, 10% owner | Sellindirect | -27,612 | $1.650 | — | 114,851 | Form 4 |
| filed | Andrew J. SchwabDirector, 10% owner | Sellindirect | -1,088 | $1.650 | — | 4,528 | Form 4 |
| filed | 5AM Ventures II LP10% owner | Sellindirect | -1,088 | $1.650 | $2 K | 4,528 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Skye Bioscience Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-8 reverse split ; 1-for-250 reverse split
Trading halts
- 2026-11-10 14:39 UTC, code LUDP, resumed 14:44 UTC
- 2026-08-21 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-08-14 14:00 UTC, code LUDP, resumed 14:05 UTC
- 2026-08-14 12:39 UTC, code T3, resumed 14:00 UTC
- 2025-04-15 13:47 UTC, code LUDP, resumed 13:57 UTC
Fails to deliver
- : 41 shares at $1.52
- : 7 shares at $1.55
- : 4,747 shares at $1.65
- : 1,467 shares at $1.62
- : 1 shares at $1.60
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Skye Bioscience Inc. scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.3×Price to book 0.3× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.41 vs -0.73Diluted EPS -1.41 in fiscal 2025 against -0.73 the year before (report's currency).
- ✗Net income higher than five years earlier-$56 M-$56 M in fiscal 2025 against -$7 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$56 MNet income -$56 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-126.8%-126.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities3.3×Current ratio 3.30 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year8.7%Diluted shares up 8.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Skye Bioscience Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 42+127%— | 19+221%— | 5.8−3.2%— | 6.0+105%— | 2.9+50.8%— | 1.9−13.1%— | 2.2+578%— | 0.3+6.0%— | 0.3−66.8%— | 0.9—— | |
| General and administrative | 16−10.9%— | 18+126%— | 7.9+28.8%— | 6.1+24.0%— | 4.9+13.2%— | 4.3−1.1%— | 4.4+0.7%— | 4.4+23.0%— | 3.5+0.5%— | 3.5—— | |
| Operating expenses | 58+92.6%— | 30−13.1%— | 35+89.7%— | 18+133%— | 7.8+24.8%— | 6.3−5.2%— | 6.6+41.3%— | 4.7+21.6%— | 3.9−13.7%— | 4.5—— | |
| Operating income | −58—— | −30—— | −35—— | −18—— | −7.8—— | −6.3—— | −6.6—— | −4.7—— | −3.9—— | −4.5—— | |
| Interest and finance income | 1.9−37.8%— | 3.0+2930%— | 0.1+426%— | 0.0+633600%— | 0.0−89.7%— | 0.0+11.5%— | 0.0−69.0%— | 0.0—— | — | — | |
| Interest expense and finance costs | 0−100%— | 0.7−17.3%— | 0.9+36.3%— | 0.7−13.5%— | 0.8+8.9%— | 0.7−29.4%— | 1.0+956%— | 0.1+14107%— | 0.0—— | — | |
| Other non-operating income (expense) | 2.2−38.3%— | 3.6—— | −2.9—— | −1.2—— | −0.7—— | −0.3−104%— | 7.7—— | −15—— | — | — | |
| Income before tax | −56—— | −27—— | −38—— | −19—— | −8.5—— | −6.6−723%— | 1.1—— | −19—— | −3.1—— | −3.2—— | |
| Income tax | 0.0−46.4%— | 0.0+180%— | 0.0−46.6%— | 0.0+221%— | 0.0+31.3%— | 0.00.0%— | 0.0−2.6%— | 0.0+2.6%— | 0.00.0%— | 0.0—— | |
| Net income attributable to shareholders | −56—— | −27—— | −38—— | −19—— | −8.5—— | −6.6−724%— | 1.1—— | −19—— | −3.1—— | −3.2—— | |
| Earnings per share, basic | -1.41—— | -0.73—— | -5.37—— | -8.77r-0.04—— | -0.02—— | -0.03−400%— | 0.01—— | -0.16—— | -0.11—— | -0.17—— | |
| Earnings per share, diluted | -1.41—— | -0.73—— | -5.37—— | -8.77r-0.04—— | -0.02—— | -0.03—— | -0.05—— | -0.16—— | -0.11—— | -0.17—— | |
| Shares, weighted average (basic) | 40+8.7%— | 36+421%— | 7.0+215%— | 2.2r555−99.5%— | 407+76.2%— | 231+70.7%— | 135+11.6%— | 121+334%— | 28+47.3%— | 19—— | |
| Shares, weighted average (diluted) | 40+8.7%— | 36+421%— | 7.0+215%— | 2.2r555−99.5%— | 407+75.7%— | 231+36.5%— | 170+40.0%— | 121+334%— | 28+47.3%— | 19—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.9−91.4%20.8% | 68+5345%94.0% | 1.3+1.0%10.5% | 1.2−86.1%13.7% | 9.0+264%91.2% | 2.5+34.9%92.4% | 1.8−1.3%91.6% | 1.9+613%94.7% | 0.3+301%46.7% | 0.1—20.0% | |
| Short-term investments | 20—70.1% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Other current assets | 0.9−61.4%3.0% | 2.2+97.3%3.0% | 1.1r0.9+133%9.4% | 0.5r0.4+747%5.3% | 0.1+20580%0.6% | 0.0r0.0−96.4%0.0% | 0.0+189%0.4% | 0.0—0.1% | — | 0.0—2.2% | |
| Current assets | 27−61.7%95.7% | 71+508%97.3% | 12+30.3%97.6% | 8.9−7.0%98.2% | 9.6+261%97.5% | 2.7+33.6%99.7% | 2.0+2.1%99.9% | 2.0+252%99.8% | 0.6+98.9%99.7% | 0.3—86.4% | |
| Property, plant and equipment | 0.9−37.3%3.2% | 1.4+3211%2.0% | 0.0−50.7%0.4% | 0.1+0.2%1.0% | 0.1+1095%0.9% | 0.0+270%0.3% | 0.0−42.4%0.1% | 0.0+145%0.2% | 0.0−85.3%0.3% | 0.0—3.0% | |
| Right-of-use (leased) assets | 0.3−40.7%0.9% | 0.4+89.0%0.6% | 0.2+234%2.0% | 0.1−51.6%0.8% | 0.1—1.5% | 0—0.0% | — | — | — | — | |
| Total assets | 28−61.1%100% | 73+509%100% | 12+31.1%100% | 9.1−7.5%100% | 9.9+269%100% | 2.7+33.8%100% | 2.0+2.0%100% | 2.0+251%100% | 0.6+72.3%100% | 0.3—100% | |
| Accounts payable | 2.0+257%7.2% | 0.6−50.7%0.8% | 1.2−30.8%9.7% | 1.7+86.0%18.3% | 0.9+146%9.1% | 0.4+181%13.6% | 0.1+732%6.5% | 0.0−84.5%0.8% | 0.1−63.3%18.1% | 0.3—84.9% | |
| Current liabilities | 8.2+89.1%29.0% | 4.3−68.8%6.0% | 14+14.7%116% | 12+210%133% | 3.9+397%39.7% | 0.8−18.9%29.5% | 1.0−93.9%48.6% | 16+1878%814% | 0.8+21.8%145% | 0.7—205% | |
| Lease liabilities (non-current) | 0.1−69.2%0.3% | 0.3+59.5%0.4% | 0.2—1.4% | 0−100%0.0% | 0.1—0.8% | 0—0.0% | — | — | — | — | |
| Non-current liabilities | — | — | — | — | — | — | — | — | 0.6−50.4%98.9% | 1.1—344% | |
| Total liabilities | 8.3+79.7%29.3% | 4.6−67.2%6.3% | 14+16.1%118% | 12+204%133% | 4.0+79.7%40.5% | 2.2+53.3%83.1% | 1.4−91.7%72.6% | 18+1191%895% | 1.4−23.5%244% | 1.8—549% | |
| Retained earnings | −187—−660% | −131—−180% | −104—−874% | −67—−732% | −47—−480% | −39—−1450% | −32—−1611% | −33—−1698% | −14—−2518% | −11—−3382% | |
| Shareholders' equity | 20−70.6%70.7% | 68—93.7% | −2.1—−17.9% | −3.0−151%−33.0% | 5.9+1201%59.5% | 0.5−17.7%16.9% | 0.5—27.4% | −16—−795% | −3.6—−641% | −2.9—−901% | |
| Total liabilities and equity | 28−61.1%100% | 73+509%100% | 12+31.1%100% | 9.1−7.5%100% | 9.9+269%100% | 2.7+33.8%100% | 2.0+2.0%100% | 2.0+251%100% | 0.6+72.3%100% | 0.3—100% | |
| Shares outstanding | 4.2r33−86.5%— | 31+151%— | 12+238%— | 3.7r914−99.2%— | 476+65.3%— | 288+57.5%— | 183+36.6%— | 134r134+298%— | 34+55.9%— | 22—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.7+142%— | 0.3+140%— | 0.1—— | — | — | — | — | — | — | — | |
| Share-based compensation | 7.8−6.6%— | 8.3+742%— | 1.0+57.0%— | 0.6−27.6%— | 0.9+187%— | 0.3−55.5%— | 0.7+0.8%— | 0.7+10.9%— | 0.6−13.8%— | 0.7—— | |
| Cash from operating activities | −43—— | −25—— | −14—— | −13—— | −6.5—— | −6.1—— | −6.0—— | −3.9—— | −3.3r−3.3—— | −3.6—— | |
| Capital expenditure | −0.0—— | −1.6—— | −0.0—— | −0.0—— | −0.1—— | −0.0—— | — | −0.0—— | −0.0—— | −0.0—— | |
| Cash from investing activities | −20—— | −0.2−104%— | 6.6+26.5%— | 5.2—— | −0.1—— | −0.0—— | — | −0.0—— | −0.0—— | −0.0—— | |
| Shares issued | — | 0−100%— | 5.0—— | 0−100%— | 6.1−0.4%— | 6.1+217%— | 1.9−38.0%— | 3.1—— | — | 0.4—— | |
| Cash from financing activities | 0.0−100.0%— | 84+408%— | 16—— | −0.2−102%— | 13+95.2%— | 6.7+11.6%— | 6.0+8.4%— | 5.5+57.7%— | 3.5+762%— | 0.4—— | |
| Change in cash | −63−208%— | 58+539%— | 9.1—— | −7.7−219%— | 6.5+919%— | 0.6—— | −0.0−101%— | 1.6+883%— | 0.2r0.2—— | −3.2—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 25−36.2%— | 1.3−85.9%— | 3.9−72.5%— | 7.9+10.3%— | 11*+47.2%— | 9.4+91.6%— | 14+252%— | 7.2+270%— | 7.8*+390%— | 4.9—— | 4.1—— | 1.9—— | 1.6*—— | |
| General and administrative | 16−7.3%— | 3.7−6.4%— | 3.9−0.9%— | 4.7+3.9%— | 3.4*−24.8%— | 3.9−15.8%— | 3.9−9.7%— | 4.6+8.5%— | 4.6*+82.6%— | 4.6—— | 4.3—— | 4.2—— | 2.5*—— | |
| Operating expenses | 39−28.4%— | −0.0−100%— | 11−39.4%— | 13+7.8%— | 15*+39.7%— | 13+167%— | 18+117%— | 12+91.1%— | 11*+161%— | 5.0—— | 8.4—— | 6.2—— | 4.1*—— | |
| Operating income | −39—— | 0.0—— | −11—— | −13—— | −15*—— | −13—— | −18—— | −12—— | −11*—— | −5.0—— | −8.4—— | −6.2—— | −4.1*—— | |
| Interest and finance income | 0.6−74.1%— | 0.0−88.3%— | 0.1−80.6%— | 0.2−72.6%— | 0.3*−62.6%— | 0.4−53.9%— | 0.5−44.5%— | 0.6+44.8%— | 0.7*+1356%— | 0.9—— | 1.0—— | 0.4r0.4—— | 0.1*—— | |
| Interest expense and finance costs | 0.0—— | 0.0—— | 0.0—— | 0.0+51.4%— | 0*—— | 0—— | 0−100%— | 0.0−99.7%— | — | −0.1—— | 0.5—— | 0.4—— | 0.4*—— | |
| Other non-operating income (expense) | 0.9−65.3%— | 0.0−91.6%— | 0.3−55.3%— | 0.2−74.9%— | 0.5*−50.7%— | 0.5−52.4%— | 0.6+21.9%— | 0.7−42.0%— | 0.9*—— | 1.1—— | 0.5—— | 1.1—— | −0.3*—— | |
| Income before tax | −38—— | 0.1—— | −11—— | −13—— | −14*—— | −13—— | −18—— | −11—— | −9.7*—— | −3.9—— | −7.9—— | −5.0—— | −4.4*—— | |
| Income tax | 0.0−37.0%— | 0—— | 0.00.0%— | 0−100%— | 0*—— | 0—— | 0.0−57.9%— | 0.00.0%— | 0*—— | 0—— | 0.0—— | 0.0—— | 0*—— | |
| Net income attributable to shareholders | −38—— | 0.1—— | −11—— | −13—— | −14*—— | −13—— | −18—— | −11—— | −9.7*—— | −3.9—— | −7.9—— | −5.0—— | −4.4*—— | |
| Earnings per share, basic | — | 0.01—— | -0.27—— | -0.32—— | — | -2.57r-0.32—— | -0.44—— | -0.28—— | — | -0.10—— | -0.20—— | -0.18—— | — | |
| Earnings per share, diluted | — | 0.01—— | -0.27—— | -0.32—— | — | -2.57r-0.32—— | -0.44—— | -0.28—— | — | -0.10—— | -0.20—— | -0.18—— | — | |
| Shares, weighted average (basic) | 5.0+0.1%— | 5.0+0.1%— | 40+0.1%— | 40+0.1%— | — | 5.0r40−87.2%— | 40+2.6%— | 40+41.6%— | — | 39—— | 39—— | 28—— | — | |
| Shares, weighted average (diluted) | 5.0+0.7%— | 5.0+0.7%— | 40+0.1%— | 40+0.1%— | — | 5.0r40−87.2%— | 40+2.6%— | 40+41.6%— | — | 39—— | 39—— | 28—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.8—94.9% | 4.8−73.9%94.9% | 8.1−66.2%73.1% | 8.1−82.4%42.0% | 5.9−91.4%20.8% | 18−72.6%44.6% | 24−67.8%45.7% | 46−44.3%71.6% | 68+5345%94.0% | 67—82.7% | 74—84.9% | 83—87.9% | 1.3—10.5% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 2.0−91.9%18.1% | 9.0−30.0%46.1% | 20—70.1% | 17—40.8% | 25—47.4% | 13—19.8% | 0—0.0% | — | — | — | — | |
| Other current assets | 0.0—0.2% | 0.0−98.6%0.2% | 0.5−34.6%4.3% | 0.2−92.7%1.2% | 0.9−61.4%3.0% | 0.9−66.0%2.2% | 0.7−72.9%1.4% | 3.2+114%5.0% | 2.2+97.3%3.0% | 2.7—3.3% | 2.7—3.1% | 1.5—1.6% | 1.1r0.9—9.4% | |
| Current assets | 5.0—99.3% | 5.0−87.4%99.3% | 11−78.3%99.3% | 19−70.5%95.6% | 27−61.7%95.7% | 40−50.0%96.6% | 51−41.9%97.0% | 63−33.4%97.3% | 71+508%97.3% | 80—97.9% | 87—99.7% | 95—99.7% | 12—97.6% | |
| Property, plant and equipment | 0.0—0.4% | 0.0−98.0%0.4% | 0.0−97.2%0.3% | 0.8−42.0%3.9% | 0.9−37.3%3.2% | 1.0−31.8%2.5% | 1.2+2454%2.2% | 1.3+3515%2.0% | 1.4+3211%2.0% | 1.5—1.9% | 0.0—0.1% | 0.0—0.0% | 0.0—0.4% | |
| Right-of-use (leased) assets | 0.0—0.2% | 0.0−97.2%0.2% | 0.0−90.5%0.3% | 0.1−85.8%0.3% | 0.3−40.7%0.9% | 0.3+68.9%0.8% | 0.4+75.1%0.7% | 0.4+84.5%0.6% | 0.4+89.0%0.6% | 0.2—0.2% | 0.2—0.2% | 0.2—0.2% | 0.2—2.0% | |
| Total assets | 5.1—100% | 5.1−87.7%100% | 11−78.8%100% | 19−70.0%100% | 28−61.1%100% | 41−49.3%100% | 52−40.2%100% | 65−31.7%100% | 73+509%100% | 82—100% | 87—100% | 95—100% | 12—100% | |
| Accounts payable | 2.4—48.3% | 2.4−13.3%48.3% | 4.3+32.8%38.8% | 3.9+130%20.3% | 2.0+257%7.2% | 2.8+262%6.8% | 3.2+199%6.2% | 1.7+56.5%2.6% | 0.6−50.7%0.8% | 0.8—1.0% | 1.1—1.2% | 1.1—1.2% | 1.2—9.7% | |
| Current liabilities | 3.7—73.2% | 3.7−55.6%73.2% | 12+38.7%105% | 10+95.6%53.6% | 8.2+89.1%29.0% | 8.4+48.8%20.2% | 8.3−42.0%15.9% | 5.3−66.3%8.2% | 4.3−68.8%6.0% | 5.6—6.9% | 14—16.4% | 16—16.7% | 14—116% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.1−69.2%0.3% | 0.1+11.2%0.3% | 0.2+32.8%0.3% | 0.2+48.0%0.3% | 0.3+59.5%0.4% | 0.1—0.1% | 0.1—0.1% | 0.2—0.2% | 0.2—1.4% | |
| Total liabilities | 3.7—73.2% | 3.7−56.3%73.2% | 12+35.9%105% | 10+87.7%53.6% | 8.3+79.7%29.3% | 8.5+48.1%20.5% | 8.5−41.3%16.3% | 5.5−65.3%8.6% | 4.6−67.2%6.3% | 5.7—7.0% | 14—16.6% | 16—16.8% | 14—118% | |
| Retained earnings | −210—−4142% | −210—−4142% | −210—−1905% | −199—−1027% | −187—−660% | −172—−417% | −160—−306% | −142—−219% | −131—−180% | −121—−149% | −117—−134% | −109—−115% | −104—−874% | |
| Shareholders' equity | 1.4—26.8% | 1.4−95.9%26.8% | −0.5−101%−4.5% | 9.0−84.8%46.4% | 20−70.6%70.7% | 33−56.7%79.5% | 44−40.0%83.7% | 59−24.9%91.4% | 68—93.7% | 76—93.0% | 73—83.4% | 79—83.2% | −2.1—−17.9% | |
| Total liabilities and equity | 5.1—100% | 5.1−87.7%100% | 11−78.8%100% | 19−70.0%100% | 28−61.1%100% | 41−49.3%100% | 52−40.2%100% | 65−31.7%100% | 73+509%100% | 82—100% | 87—100% | 95—100% | 12—100% | |
| Shares outstanding | 4.4—— | 4.4−85.7%— | 35+13.4%— | 35+13.4%— | 4.2r33−86.5%— | 31+2.1%— | 31+10.4%— | 31+10.4%— | 31+151%— | 30—— | 28—— | 28—— | 12—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.5−24.6%— | 0.0*−82.5%— | 0.2*−15.8%— | 0.2−2.5%— | 0.2*+2.7%— | 0.2*+276%— | 0.2*+528%— | 0.2+544%— | 0.2r0.2*+103%— | 0.0—— | 0.0*—— | 0.0—— | 0.1*—— | |
| Share-based compensation | 6.2−24.9%— | 1.8−6.1%— | 1.3−37.5%— | 1.5−32.0%— | 1.6*−22.5%— | 1.9−0.4%— | 2.0+11.2%— | 2.2−11.1%— | 2.1*+252%— | 1.9—— | 1.8—— | 2.5—— | 0.6*—— | |
| Cash from operating activities | −31—— | −5.1*—— | −7.1*—— | −8.6—— | −9.8*—— | −13*—— | −11*—— | −9.2—— | −8.2*—— | −5.3*—— | −7.1*—— | −4.7—— | −3.8*—— | |
| Capital expenditure | 0—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | −0.0—— | −0.1*—— | −1.5*—— | −0.0*—— | −0.0—— | −0.0*—— | |
| Cash from investing activities | 17—— | 2.0*−75.0%— | 7.1*—— | 11—— | −2.8*−3201%— | 8.0*—— | −12*—— | −13−1222%— | 0.1*—— | −1.4*—— | −0.0*—— | 1.1—— | −0.0*—— | |
| Shares issued | — | — | — | — | — | — | — | — | −84*—— | — | — | — | −6.8*—— | |
| Cash from financing activities | −0.3−1269%— | −0.1*—— | −0.1*−656%— | −0.1—— | 0.0*+103%— | 0*—— | 0.0*—— | 0−100%— | 0.0*—— | 0*—— | −2.1*—— | 86—— | −0.0*—— | |
| Change in cash | −14—— | −3.3*—— | −0.1*—— | 2.3—— | −13*—— | −5.4*—— | −23*—— | −22−127%— | −8.1*—— | −6.7*—— | −9.2*—— | 82—— | −3.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Skye Bioscience Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Skye Bioscience Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Dhillon | $1.4 M | −$148 K | $882 K | $19 |
| 2024Punit Dhillon | $6.1 M | $2.8 M | $2.2 M | $70 |
| 2023Punit Dhillon | $1.8 M | $1.3 M | $1.3 M | $67 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Skye Bioscience Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Auditor changed 1 · Change in control 1 · Directors and officers 10 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Directors and officersAgreement ended | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changed | 8-K/A | |
| Delisting notice | 8-K | |
| Change in controlDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 11, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $40 M | Private placement after listing | $10 to $50 million | 13 | equity | SEC |
| Jan 2024 | $50 M | Private placement after listing | $10 to $50 million | 11 | equity, options | SEC |
| Aug 2023 | $62 M | Private placement after listing | $50 to $250 million | 12 | equity, debt, options | SEC |
| Nov 2018 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity, debt, options | SEC |
| Jan 2018 | $4 M | Private placement after listing | $2 to $10 million | 2 | equity, debt, options | SEC |
| Nov 2017 | $2 M | Private placement after listing | $2 to $10 million | 2 | equity | SEC |
| Jan 2017 | $1 M | Private placement after listing | Under $2 million | 5 | equity | SEC |
| Aug 2015 | $5 M | Private placement after listing | $2 to $10 million | 15 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Skye Bioscience Inc. compares in Biotechnology
- Market cap$7 M · higher than 8% of 726
- Price / book0.3× · lower than 96% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Skye Bioscience Inc.🇺🇸 | $7 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 9, 2026
- Profile updated:
- Nov 19, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Skye Bioscience Inc.? Verify and update this profile — free
Show Skye Bioscience Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.